Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (7533)	7/23/2001 1:21:52 AM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

Hi Dave, The article by Leonard Zehr also mentioned the $150 million Cdn valuation for OXO all those years ago. In order to acquire the remaining 80% at those old prices we would need to come up with $120 million. It's becoming far more interesting and also more volatile. I've heard numerous theories now about valuations of that 80% - but I believe the one thing we can say is that it isn't cheaper than years ago. While I suspect the acquision of OXO was always in DMX plans, it is blunt truth that the onus is more on Pennsaid than ever to deliver the means without severe dilution. The investment community didn't see this news as either adding or taking away from DMX. It didn't react at all. What is clear to me is that Ms Keeler is either very confident that she can satisfy FDA requirements - or that she may have over reached. Europe/Canada/Carribean do not fund this. Without the shareprice appreciation and additional cash/cash flow that accompany the US market for Pennsaid - this dog does not hunt. To me that's clear. I agree with the almost universal support by current shareholders that this is a good move. Coming to the NAZ with a PO with fast tracking and good publicity could swing it I suppose. At what price and quantity though when investors see in the prospectus that Dimethaid's experience is with Pennsaid if it is still not approved in the US? Like I said before, this is a bold move that speaks of a lot of confidence inside Dimethaid. I stay and back her. This has a ton of potential. Good luck with it. It's certainly not boring anymore. And unlike Pennsaid - it should soon be obvious WF10 saves lives. Bringing it to the world is worth the price and the risk to me. Not to mention the potential rewards. Wolf